A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study To Evaluate The Efficacy And Safety Of Rivipansel (Gmi-1070) In The Treatment Of Vaso-occlusive Crisis In Hospitalized Subjects With Sickle Cell Disease
Phase of Trial: Phase III
Latest Information Update: 12 Aug 2017
At a glance
- Drugs Rivipansel (Primary)
- Indications Sickle cell anaemia
- Focus Registrational; Therapeutic Use
- Acronyms RESET
- Sponsors Pfizer
- 01 Mar 2017 According to a Glycomimetics media release, the enrollment in this trial is expected to be completed in the second half of 2018.
- 06 Jul 2015 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
- 23 Jun 2015 According to a Pfizer media release, first patient has been dosed in this study.